TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03862794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: new social norm feedback letter with bar chart
Description: letter with the percentile prescribing the practice is on and a bar chart, comparing prescribing to the national average

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: new social norm feedback letter with bar chart
Description: letter with the percentile prescribing the practice is on and a bar chart, comparing prescribing to the national average

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: new social norm feedback letter with bar chart
Description: letter with the percentile prescribing the practice is on and a bar chart, comparing prescribing to the national average

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard social norm feedback letter
Description: social norm feedback letter used as standard practice, without specific information about the prescribing percentile

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard social norm feedback letter
Description: social norm feedback letter used as standard practice, without specific information about the prescribing percentile
Study: NCT04069832

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Single-Session Consultation
Description: A single, goal-directed consultation session based on Solution-Focused Brief Therapy (SFBT). SFBT is an evidence-based therapy approach that is primarily focused on the client's present problems and their immediate future. When using SFBT in a single-session the aim of the intervention becomes empowering the client to take the smallest possible steps towards their desired future.
Study: NCT02269410

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GBP-SPS
Description: Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GBP-HPS
Description: Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VSG-SPS
Description: Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSG-HPS
Description: Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
Study: NCT02662764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalviso™ 15 mcg
Description: Zalviso™ (sufentanil sublingual tablet system) 15 mcg. Tablets to be self-administered by the patient as needed for pain, no more than every 20 minutes, for 24 hours and up to 72 hours
Study: NCT02544425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Subjects will receive Etoposide 100 mg/m2 + 5% dextrose in water 500 mL intravenous over 90 mins D1-3 of VIDL chemotherapy. After that, Etoposide will be administered 375mg/m2 D1-2 with G-colony stimulating factor (10 ug/kg) injection in step of Peripheral Blood Stem Cell Collection. Also It will be administered 400mg/m2 on conditioning regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: It will be administered1.2g/m2 + 5% dextrose in water 100 mL intravenous over 1 hr D1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: It will be administered 40mg/day PO or IV D1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase
Description: It will be administered 4000 IU/m2 intramuscular D8, 10, 12, 14, 16, 18, 20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Conditioning regimen for autologous stem cell transplantation:~Busulfan 3.2 mg/kg D -8, -7, -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Conditioning regimen for autologous stem cell transplantation:~Melphalan 70 mg/m2 D -3, -2
Study: NCT03061448

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based cognitive-behavior therapy
Description: Internet-based cognitive-behavior therapy on a safe internet platform. Treatment is divided into eight modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hours.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavior therapy
Description: Internet-based cognitive-behavior therapy on a safe internet platform. Treatment is divided into eight modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hours.
Study: NCT01291225

Intervention type: OTHER
Group type: OTHER
Intervention: Playground renovation and development
Description: Playgrounds in Chillicothe will be renovated based on priorities determined by audits.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational campaign
Description: Educational materials will be developed and distributed in Ross County.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational campaign
Description: Educational materials will be developed and distributed in Ross County.
Study: NCT03329521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Description: Patients in 13 of the 26 CKD programs will receive a multicomponent intervention or usual care. The intervention has four main components: (1) support for local quality improvement teams and administrative needs; (2) tailored education and resources for staff, patients, and living kidney donor candidates; (3) support from kidney transplant recipients and living kidney donors; and (4) program-level performance reports and oversight by program leaders.
Study: NCT03340558

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: MEK inhibitor
Study: NCT03313258

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Group
Description: ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is blinded to the care team but not to the research personnel.
Study: NCT02263248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venlafaxine
Description: slow titration to a maximum of 300 mg per day. will remain on venlafaxine XR for upto 32 weeks.
Study: NCT03313258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Warming Group
Description: ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is un-blinded to everyone so healthcare practitioners will be able to visually detect continuous temperature readings from the ZHF monitor.
Study: NCT03764423

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salmon fishmeal
Description: Salmon fishmeal with high protein content

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline cellulose
Description: Microcrystalline cellulose contain no energy and is less fermented in the gut than other dietary fibers.
Study: NCT01267253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib Alaninate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02377960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMB model-based initiation of antihypertensive medication
Description: 1.An IMB model-based initiation of medication i.e. a nine-point check list to be fulfilled by physician and patient together when ordering the antihypertensive medication for the first time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMB model-based initiation of antihypertensive medication
Description: 1.An IMB model-based initiation of medication i.e. a nine-point check list to be fulfilled by physician and patient together when ordering the antihypertensive medication for the first time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored SMS-text message support
Description: 2.Tailored SMS-text message support for the first 12 months of medication. At the beginning (2 weeks), text messages are send on daily basis and focused on medications-reminders and coping with potential side-effects of medication. After that, text messages will be sent less often and the focus will change to keeping up with medication and reminding of importance of performing adequate home BP self-monitoring, achieving the BP target and attending clinical appointments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored SMS-text message support
Description: 2.Tailored SMS-text message support for the first 12 months of medication. At the beginning (2 weeks), text messages are send on daily basis and focused on medications-reminders and coping with potential side-effects of medication. After that, text messages will be sent less often and the focus will change to keeping up with medication and reminding of importance of performing adequate home BP self-monitoring, achieving the BP target and attending clinical appointments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care
Study: NCT02263248

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: venlafaxine
Description: slow titration to a maximum of 300 mg per day. will remain on venlafaxine XR for upto 32 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine
Description: randomized to either buprenorphine or placebo, dose range from 0.2 mg qd/ to 1.2 mg qd
Study: NCT00147225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=11; Cycle 1 chemotherapy alone then 3 weeks later, in Cycle 2, same dose of chemotherapy followed by AMG 531.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=11; Cycle 1 chemotherapy alone then 3 weeks later, in Cycle 2, same dose of chemotherapy followed by AMG 531.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=11; Cycle 1 chemotherapy alone then 3 weeks later, in Cycle 2, same dose of chemotherapy followed by AMG 531.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=11; Cycle 1 chemotherapy alone then 3 weeks later, in Cycle 2, same dose of chemotherapy followed by AMG 531.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=11; Cycle 1 chemotherapy alone then 3 weeks later, in Cycle 2, same dose of chemotherapy followed by AMG 531.
Study: NCT02840175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: will be tapered from every week to every 2 weeks for 12 weeks then to every 3 weeks for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: will be tapered from every 2 weeks to every 3 weeks for 12 weeks and to every 4 weeks for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: will be tapered from every 2 weeks to every 3 weeks for 12 weeks and to every 4 weeks for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: will be tapered from every 4 weeks to every 6 weeks for 24 weeks
Study: NCT00147225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: 75-90 mg/m\^2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: 75-90 mg/m\^2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: 75-90 mg/m\^2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: 75-90 mg/m\^2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: 75-90 mg/m\^2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: 75-90 mg/m\^2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 10 gm/m\^2 IV; OR, High dose ifosfamide = 14 gm/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 10 gm/m\^2 IV; OR, High dose ifosfamide = 14 gm/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 10 gm/m\^2 IV; OR, High dose ifosfamide = 14 gm/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 10 gm/m\^2 IV; OR, High dose ifosfamide = 14 gm/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 10 gm/m\^2 IV; OR, High dose ifosfamide = 14 gm/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 10 gm/m\^2 IV; OR, High dose ifosfamide = 14 gm/m\^2.
Study: NCT02263248

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients will remain on venlafaxine XR and be randomzied to receive either placebo or buprenorphine for 8 weeks. at the end of 8 weeks those who did not receive buprenorphine will be given an opportunity to try it.
Study: NCT04285424

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: The fecal collection produced from a single healthy donor, unrelated to the patients
Study: NCT02032381

Intervention type: OTHER
Group type: OTHER
Intervention: late pulmonary complications occurring in children treated with allogeneic hematopoietic stem cells.
Study: NCT03470714

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Force Irradiation
Description: For the force irradiation, while the subjects perform dominant elbow flexion at an angular velocity of 60°/s for concentric contractions, 30°/s for eccentric contractions, at 90° elbow flexion position for isometric contractions with a maximal effort level, electrical activity of the non-dominant biceps brachii and triceps brachii muscles are recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Force Irradiation
Description: For the force irradiation, while the subjects perform dominant elbow flexion at an angular velocity of 60°/s for concentric contractions, 30°/s for eccentric contractions, at 90° elbow flexion position for isometric contractions with a maximal effort level, electrical activity of the non-dominant biceps brachii and triceps brachii muscles are recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: For kinesiotaping, the elbow positioned in 30°-45° flexion and kinesiotaping facilitation technique is applied origin to insertion of non-dominant biceps brachii muscle before 24 hours the experiment.
Study: NCT04070677

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ziverel
Description: Patients in treatments with radiotherapy alone (RT) or radiochemotherapy (RT-CH) with acute radiation-induced esophagitis grade 2 or superior according to the most recent CTCAE will received support treatment with ZIVEREL®
Study: NCT01628627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Frequency Modulated Neural Stimulation (FREMS) (Aptiva)
Description: FREMS consisted of sequences of biphasic (negative and positive), asymmetric and electrically balanced pulses, composed of: 1) an active phase of high negative voltage spike (variable, max -300 V) and extra short duration (variable, 10-100 μsec, mostly \~40 μsec); followed by: 2) a recharging phase of low voltage and long duration (0.9 - 999 msec); pulse frequency was variable, ranging 1 to 1,000 Hz, mainly in the low range 1-50 Hz. Three cycles of 10 consecutive (one a day for 5 days/week) applications to both lower limbs were delivered.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham treatment (Aptiva)
Description: The sham treatment consisted of no electrical pulses delivered by the same device used to deliver the FREMS treatment and with the same treatment procedure and schedule.
Study: NCT01302938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine ER
Description: One 4 mg capsule will be taken with water every day with or without food. It should be swallowed whole without chewing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo of Tolterodine ER 4 mg will be taken with water every day with or without food. It should be swallowed whole without chewing.
Study: NCT03019003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Decitabine
Description: Hypomethylating agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: anti-PD-L1
Study: NCT02294474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR342434
Description: SAR342434 100 U/mL (dose range of 1 Unit to 80 Units) self-administered by subcutaneous (SC) injection, immediately (within 5 -10 minutes) before meals intake. Dose adjusted to achieve 2 hour post prandial glucose (PPG) in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog
Description: Humalog 100 U/ml (dose range of 1 unit to 60 units) self-administered by SC injection, immediately (within 5-10 minutes) before meals intake. Dose adjusted to achieve a 2 hour PPG in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine HOE901
Description: Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine HOE901
Description: Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
Study: NCT02140346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1729 28 day repeat dose
Description: Safety and tolerability of repeat doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1729 28 day repeat dose
Description: Safety and tolerability of repeat doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1729 matching placebo 28 day repeat dose
Description: Safety and tolerability of repeat doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1729 matching placebo 28 day repeat dose
Description: Safety and tolerability of repeat doses
Study: NCT04220671

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: measles vaccine
Description: Measles vaccine, Edmonston-Zagreb strain, 0.5 ml administered as a subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.9% NaCl
Study: NCT03178513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visit
Description: The visit will be entirely patient tailored, last approximately one hour, and at a minimum will entail:~* Medical assessment~* Psychosocial assessment~* Medication reconciliation~* Follow-up of inpatient primary team's specific recommendations~* Follow-up, as needed, with primary care team or inpatient team
Study: NCT03077620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Participants will be given a sleep aid (10mg or 20mg suvorexant) at bedtime for two consecutive nights that they are spending in a research unit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Participants will be given a sleep aid (10mg or 20mg suvorexant) at bedtime for two consecutive nights that they are spending in a research unit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be given a placebo at bedtime for two consecutive nights that they are spending in a research unit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be given a placebo at bedtime for two consecutive nights that they are spending in a research unit.
Study: NCT03472300

Intervention type: OTHER
Intervention: Survey about knee pain and treatment
Description: All citizens are surveyed to describe the prevalence of knee pain in a danish community.